SHAREHOLDER ALERT: Levi & Korsinsky, LLP Informs Shareholders of an Investigation into The Oncology Institute-Inc.

NEW YORK, NY / ACCESSWIRE / October 3, 2024 /The following statement is being issued by Levi & Korsinsky, LLP:

To: All Persons or Entities who own The Oncology Institute, Inc. ("TOI" or the "Company") (NASDAQ:TOI) stock purchased prior to November 9, 2021.

You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of the company, then known as DFP Healthcare Acquisitions Corp. (DFPH), and whether the Board of TOI harmed stockholders, and whether all material facts had been properly disclosed to stockholders. .

To learn more about the action and your rights, go to:

https://zlk.com/mna2/oncology-institute-inc-the-lawsuit-submission-form?prid=153&wire=1

or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call (212) 363-7500 to speak to our team of experienced shareholder advocates.

The TOI merger investigation concerns whether the board of The Oncology Institute, Inc. have harmed stockholders by agreeing to enter into this transaction and whether all material facts have been properly disclosed to stockholders.

Levi & Korsinsky is a nationally recognized firm with offices in New York, Connecticut, California, and Washington, D.C. The firm 's attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities lawsuits and have recovered hundreds of millions of dollars for aggrieved shareholders. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
https://zlk.com/

SOURCE:Levi & Korsinsky, LLP

View the original press release on accesswire.com

© 2024 Accesswire. All Rights Reserved.